Skip to main content
    I

    Integra LifeSciences Holdings (IART)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $13.55
    -0.43 (-3.08%)

    Market Cap: $1.09B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Integra LifeSciences Holdings (IART) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Integra LifeSciences Holdings (IART) has a market cap of $1.09B and an enterprise value of $2.82B. Its trailing P/E of 5.4x is below its 10-year median of 19.5x. Its net debt of $1.74B equals 159.61% of its market cap.

    Total Valuation

    Enterprise value is 159.61% above the market cap, as debt exceeds cash.

    Market Cap$1.09B
    Enterprise Value$2.82B
    Latest price (Nov 17, 2026)$13.55

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateOct 21, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.12% in the quarter ended Sep 30, 2026 and grew 0.61% a year over 2 years.

    Shares Outstanding77.39M
    Shares Change (YoY)+0.83%
    Shares Change (QoQ)+0.12%
    Share Count Growth (2Y CAGR)+0.61%

    Valuation Ratios

    Sales and book value multiples are 0.6x and 1.0x. Its year-end P/E ranged from 5.6x to 26.5x from 2016 to 2025.

    P/E Ratio5.4x
    Forward P/E5.7x
    P/S Ratio0.6x
    Forward P/S0.7x
    P/B Ratio1.0x
    P/FCF Ratio12.2x
    P/OCF Ratio7.7x
    PEG Ratio1.1

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 10.9x EBITDA and 32.5x free cash flow.

    EV / Earnings216.9x
    EV / Sales1.7x
    EV / EBITDA10.9x
    EV / EBIT29.2x
    EV / FCF32.5x

    Price Statistics

    The stock is up 15.32% over 52 weeks and trades 4.64% below its 50-day average.

    Beta (1Y)1.57
    52-Week Change+15.32%
    1-Month Change+0.74%
    3-Month Change-21.40%
    6-Month Change-5.77%
    5-Year Change-80.82%
    10-Year Change-67.93%
    Total Return (1Y)+15.32%
    Total Return (3Y CAGR)-29.54%
    Total Return (5Y CAGR)-27.58%
    Return vs SPY (1Y)+7.09%
    Max Drawdown (1Y)-40.35%
    Max Drawdown (3Y)-80.31%
    Sharpe Ratio (1Y)0.28
    Correlation with SPY (1Y)0.35
    50-Day Average$14.21
    200-Day Average$14.21
    52-Week Range$8.70 to $20.49
    RSI (14 Days)47.2
    Average Volume (20 Days)1.23M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.62x current liabilities, and total debt is 1.86x shareholder equity.

    Current Ratio3.62x
    Quick Ratio2.21x
    Debt / Equity1.86x
    Debt / EBITDA7.80x
    Debt / FCF23.17x
    Interest Coverage1.05x

    Returns and Efficiency

    Return on invested capital is 2.06% over the last 12 months, against a 5-year average of 0.22%.

    Return on Equity (ROE)1.22%
    Return on Assets (ROA)0.37%
    Return on Invested Capital (ROIC)2.06%
    Return on Capital Employed (ROCE)3.04%
    ROE (5Y Average)-5.13%
    ROA (5Y Average)-0.72%
    ROIC (5Y Average)0.22%
    Asset Turnover0.46x
    Inventory Turnover1.65x
    Receivables Turnover6.42x
    Cash Conversion Cycle244 days

    Taxes

    Income tax took 41.67% of pretax income over the last 12 months.

    Income Tax (TTM)$9.30M
    Effective Tax Rate41.67%

    Scores

    IART has an Altman Z-Score of 1.29, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score1.29
    Altman Z ZoneDistress
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $1.66B over the last 12 months is up 0.84% from the 12 months before.

    Revenue$1.66B
    Revenue Growth (YoY)+0.84%
    Gross Profit$867.46M
    Operating Income$72.69M
    Pretax Income$22.31M
    Net Income$13.01M
    EBITDA$254.82M
    EBIT$96.67M
    Reported EPS (TTM)$2.52

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 30.48% of the $3.51B in total assets.

    Cash and Equivalents$252.26M
    Total Debt$1.99B
    Net Debt$1.74B
    Net Debt Per Share$22.43
    Working Capital$860.94M
    Shareholder Equity$1.07B
    Book Value Per Share$13.78
    Tangible Book Value-$581.85M
    Total Assets$3.51B
    Total Liabilities$2.44B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $54.62M of capital spending, operating cash flow left $85.78M of free cash flow.

    Operating Cash Flow$140.40M
    Capital Expenditures$54.62M
    Free Cash Flow$85.78M
    FCF Per Share$1.10
    Depreciation and Amortization$158.15M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 4.39%, against a 5-year average of 1.39%.

    Gross Margin52.36%
    Operating Margin4.39%
    Pretax Margin1.35%
    Net Margin0.79%
    EBITDA Margin15.38%
    EBIT Margin5.83%
    FCF Margin5.18%
    Gross Margin (5Y Average)57.31%
    Operating Margin (5Y Average)1.39%
    Net Margin (5Y Average)-1.01%

    Growth

    Revenue grew 1.63% a year over 3 years, and EPS fell 12.77% a year.

    Revenue Growth (3Y CAGR)+1.63%
    Revenue Growth (5Y CAGR)+3.57%
    EPS Growth (3Y CAGR)-12.77%
    EPS Growth (5Y CAGR)-1.86%
    Book Value Per Share Growth (2Y CAGR)-18.11%

    Revenue and profit by year

    Dividends and Yields

    IART does not pay a dividend. Its free cash flow yield is 8.18%.

    Earnings Yield18.52%
    FCF Yield8.18%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 2-for-1 forward split on Jan 4, 2017.

    Last Split DateJan 4, 2017
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 6 similar companies, IART has the lowest P/E.

    P/E Ratio5.4x vs 34.5x median
    P/S Ratio0.6x vs 5.0x median
    ROIC2.06% vs -18.01% median
    Revenue Growth (Trailing 4 Quarters, YoY)+0.84% vs +15.12% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 1.20% and EPS growth at 3.08% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+1.20%
    EPS Growth Forecast (2Y CAGR)+3.08%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About IART

    What is IART's market cap?

    Integra LifeSciences Holdings has a market cap of $1.09B. Its enterprise value, which adds debt and subtracts cash, is $2.82B.

    What is IART's P/E ratio?

    Integra LifeSciences Holdings has a trailing P/E ratio of 5.4x and a forward P/E of 5.7x.

    How many shares of IART are outstanding?

    Integra LifeSciences Holdings has 77.39M shares outstanding. The count is up 0.83% from a year earlier.

    Does IART pay a dividend?

    No. Integra LifeSciences Holdings does not pay a dividend.

    How much debt does IART have?

    Integra LifeSciences Holdings has $1.99B of total debt and $252.26M of cash and equivalents, a net debt position of $1.74B.